Skip Navigation LinksHome > February 2012 - Volume 112 - Issue 2 > FDA Review of Antismoking Aid, Varenicline, and Neuropsychia...
AJN, American Journal of Nursing:
doi: 10.1097/
Drug Watch

FDA Review of Antismoking Aid, Varenicline, and Neuropsychiatric Adverse Events

Aschenbrenner, Diane S. MS, RN

Collapse Box


* After reviewing two epidemiologic studies on the smoking cessation aid varenicline (Chantix), the Food and Drug Administration has concluded that the drug doesn't pose any greater risk of serious mood and behavior changes than the use of nicotine replacement therapy.

* Additional information about the safety risks of varenicline may be gleaned from a clinical trial sponsored by the drug manufacturer that will be completed in 2017.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Level Metrics